1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Formulation Development Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Formulation Development Outsourcing Market, by Service
8.1.1. Preformulation
8.1.1.1. Market Revenue and Forecast
8.1.2. Formulation Development
8.1.2.1. Market Revenue and Forecast
9.1. Formulation Development Outsourcing Market, by Formulation
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast
9.1.3. Injectable
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. Formulation Development Outsourcing Market, by Therapeutic Area
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast
10.1.2. Infectious Disease
10.1.2.1. Market Revenue and Forecast
10.1.3. Respiratory
10.1.3.1. Market Revenue and Forecast
10.1.4. Cardiovascular
10.1.4.1. Market Revenue and Forecast
10.1.5. Neurology
10.1.5.1. Market Revenue and Forecast
10.1.6. Hematology
10.1.6.1. Market Revenue and Forecast
10.1.7. Dermatology
10.1.7.1. Market Revenue and Forecast
10.1.8. Others
10.1.8.1. Market Revenue and Forecast
11.1. Formulation Development Outsourcing Market, by End-User
11.1.1. Pharmaceutical Industries
11.1.1.1. Market Revenue and Forecast
11.1.2. Research and Academic Institutions
11.1.2.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service
12.1.2. Market Revenue and Forecast, by Formulation
12.1.3. Market Revenue and Forecast, by Therapeutic Area
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service
12.1.5.2. Market Revenue and Forecast, by Formulation
12.1.5.3. Market Revenue and Forecast, by Therapeutic Area
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service
12.1.6.2. Market Revenue and Forecast, by Formulation
12.1.6.3. Market Revenue and Forecast, by Therapeutic Area
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service
12.2.2. Market Revenue and Forecast, by Formulation
12.2.3. Market Revenue and Forecast, by Therapeutic Area
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service
12.2.5.2. Market Revenue and Forecast, by Formulation
12.2.5.3. Market Revenue and Forecast, by Therapeutic Area
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service
12.2.6.2. Market Revenue and Forecast, by Formulation
12.2.6.3. Market Revenue and Forecast, by Therapeutic Area
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service
12.2.7.2. Market Revenue and Forecast, by Formulation
12.2.7.3. Market Revenue and Forecast, by Therapeutic Area
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service
12.2.8.2. Market Revenue and Forecast, by Formulation
12.2.8.3. Market Revenue and Forecast, by Therapeutic Area
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service
12.3.2. Market Revenue and Forecast, by Formulation
12.3.3. Market Revenue and Forecast, by Therapeutic Area
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service
12.3.5.2. Market Revenue and Forecast, by Formulation
12.3.5.3. Market Revenue and Forecast, by Therapeutic Area
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service
12.3.6.2. Market Revenue and Forecast, by Formulation
12.3.6.3. Market Revenue and Forecast, by Therapeutic Area
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service
12.3.7.2. Market Revenue and Forecast, by Formulation
12.3.7.3. Market Revenue and Forecast, by Therapeutic Area
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service
12.3.8.2. Market Revenue and Forecast, by Formulation
12.3.8.3. Market Revenue and Forecast, by Therapeutic Area
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service
12.4.2. Market Revenue and Forecast, by Formulation
12.4.3. Market Revenue and Forecast, by Therapeutic Area
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service
12.4.5.2. Market Revenue and Forecast, by Formulation
12.4.5.3. Market Revenue and Forecast, by Therapeutic Area
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service
12.4.6.2. Market Revenue and Forecast, by Formulation
12.4.6.3. Market Revenue and Forecast, by Therapeutic Area
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service
12.4.7.2. Market Revenue and Forecast, by Formulation
12.4.7.3. Market Revenue and Forecast, by Therapeutic Area
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service
12.4.8.2. Market Revenue and Forecast, by Formulation
12.4.8.3. Market Revenue and Forecast, by Therapeutic Area
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service
12.5.2. Market Revenue and Forecast, by Formulation
12.5.3. Market Revenue and Forecast, by Therapeutic Area
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service
12.5.5.2. Market Revenue and Forecast, by Formulation
12.5.5.3. Market Revenue and Forecast, by Therapeutic Area
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service
12.5.6.2. Market Revenue and Forecast, by Formulation
12.5.6.3. Market Revenue and Forecast, by Therapeutic Area
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. SGS S.A.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eurofins Scientific SE
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Element
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Labcorp
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Thermo Fisher Scientific, Inc. (Patheon)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Intertek Group plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Recipharm
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Lonza
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Charles River Laboratories International, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Catalent Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
